BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/25/2016 7:04:00 PM | Browse: 1062 | Download: 1723
 |
Received |
|
2015-08-27 09:14 |
|
Peer-Review Started |
|
2015-08-31 11:07 |
|
To Make the First Decision |
|
2015-09-29 12:43 |
|
Return for Revision |
|
2015-10-08 18:34 |
|
Revised |
|
2015-10-21 17:00 |
|
Second Decision |
|
2015-12-01 10:42 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2015-12-16 08:41 |
|
Articles in Press |
|
2015-12-16 08:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2015-12-18 21:57 |
|
Typeset the Manuscript |
|
2016-01-23 16:52 |
|
Publish the Manuscript Online |
|
2016-02-25 19:03 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zahariy Krastev, Deian Jelev, Krasimir Antonov, Tanya Petkova, Evelina Atanasova, Nadezhda Zheleva, Bojidar Tomov, Yana Boyanova and Lyudmila Mateva |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zahariy Krastev, MD, PhD, DSc (Med), Professor of Medicine, Clinic of Gastroenterology, University Hospital “St. Ivan Rilski”, 15 Acad. Ivan Geshov Blvd, 1431 Sofia, Bulgaria. zahkrastev@gmail.com
|
| Key Words |
ombitasvir; paritaprevir; ritonavir; dasabuvir; ribavirin; hepatitis C virus cirrhosis; hepatocellular carcinoma |
| Core Tip |
Interferon-free regimens based on a com-bination of different direct acting antivirals (DAAs) are intensively studied in patients with hepatitis C virus (HCV)-related cirrhosis who are previous null responders or relapsers to interferon/ribavirin. DAAs are very effective and relatively safe in compensated cirrhosis, but there are no data regarding patients with successfully treated hepatocellular carcinoma (HCC). These two cases are the first reports on the efficacy, safety and tolerability of an ombitasvir/paritaprevir/ritonavir plus dasabuvir and ribavirin therapy in subjects with HCV cirrhosis and fully destroyed early HCC, as well as on an evaluation of the serum level of total bile acids during therapy and 12 wk thereafter.
|
| Publish Date |
2016-02-25 19:03 |
| Citation |
Krastev Z, Jelev D, Antonov K, Petkova T, Atanasova E, Zheleva N, Tomov B, Boyanova Y, Mateva L. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. World J Gastroenterol 2016; 22(8): 2630-2635 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i8/2630.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i8.2630 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
